Table 2. Factors associated with adherence to ART (measured as continuous variable).

Variable		Adherence, % 1	P	Adjusted P
Age (n = 133)	<42 years (n = 46)	100 (94.2–100)	0.49	0.27
	42–52 years (n = 42)	98.2 (94.4–100)
	>52 years (n = 45)	100 (95.6–100)	0.27	0.60
Gender (n = 133)	Female (n = 12)	96.4 (88.9–100)	0.14	0.69
	Male (n = 121)	100 (95.5–100)
Transmission route	Heterosexual (n = 23)	96.5 (88.4–100)
(n = 120)	Intravenous drug use (n = 1)	96.9
	MSM (n = 96)	100 (96.4–100)	0.033	0.67
Education (n = 128)	Low (n = 33)	98.2 (94.2–100)	0.79	0.30
	Middle (n = 46)	98.7 (91.3–100)
	High (n = 49)	100 (96.9–100)	0.12	0.73
Currently employed	Yes (n = 83)	100 (95.5–100)
(n = 122)	No (n = 39)	100 (96.5–100)	0.44	0.73
Antiretroviral therapy	NNRTI (n = 77)	99.2 (94.7–100)
(n = 128)	PI (n = 37)	100 (96.7–100)	0.39	0.44
	Other (n = 14)	98.2 (93.3–100)	0.88	0.96
Dosing regimen	One dose/day (n = 80)	100 (96.4–100)
(n = 133)	Two doses/day (n = 53)	98.2 (92.4–100)	0.036	0.014
Time on	<30 months (n = 43)	99.2 (95.5–100)	0.37	0.93
therapy (n = 129)	30–72 months (n = 44)	98.2 (91.9–100)
	>72 months (n = 42)	100 (95.7–100)	0.26	0.40
Time on therapy with	<24 months (n = 41)	99.2 (95.1–100)	0.49	0.84
undetectable plasma	24–65 months (n = 46)	98.2 (92.6–100)
viral load (n = 129)	>65 months (n = 42)	100 (96.0–100)	0.25	0.045
Current CD4+ T cell	<450 cells/mm3 (n = 43)	100 (97.3–100)	0.71	0.65
count (n = 127)	450–660 cells/mm3 (n = 39)	100 (96.5–100)
	>660 cells/mm3 (n = 45)	97.3 (91.5–100)	0.030	0.008
CD4+ T cell count	<100 cells/mm3 (n = 41)	100 (96.5–100)	0.26	0.29
nadir (n = 128)	100–200 cells/mm3 (n = 46)	98.7 (90.6–100)
	>200 cells/mm3 (n = 41)	100 (96.4–100)	0.24	0.034
Current plasma viral	>50 copies/ml (n = 9)	96.5 (73.2–100)	0.19	0.35
load (n = 127)	<50 copies/ml (n = 118)	100 (94.7–100)

¹Data are medians (interquartile ranges).